RxDoctor Payments DataLook up a doctor →

Anthony Kim, MD

Urology · Middlebury, CTNPI 1205890381

Payments from drug & device makers

$14,488in general payments, 2019–2025

Across 558 payments — averaging $25.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Astellas Pharma US Inc$1K
  • Sumitomo Pharma America, Inc.$984
  • Antares Pharma, Inc.$870
  • Pfizer$665
  • C. R. Bard, Inc. & Subsidiaries$623
  • plus $9K from 47 others

What the payments were for

  • Food & beverage$13,05690%
  • Education$1,43210%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,488 in reported general payments places this provider in the 80th percentile of 156 urology providers in Connecticut.

See all urology providers in Connecticut

Medicare billing

Part B allowed, 2024
$330,519
Medicare patients
885
Services billed
7,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide23$341,075
GemtesaVibegron194$246,546
OrgovyxRelugolix73$197,571
MyrbetriqMirabegron48$51,139
ElmironPentosan Polysulfate Sodium14$23,863
Tamsulosin Hcl1,341$19,714
Finasteride596$6,487
Methenamine Hippurate67$5,624
Solifenacin Succinate80$5,222
Silodosin49$4,633
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst103$4,607
Potassium Citrate ErPotassium Citrate54$3,617
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav77$2,962
Oxybutynin Chloride ErOxybutynin Chloride96$2,656
Dutasteride83$2,236

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$984$444,117267 claims
Johnson & JohnsonErleada$1,329$341,07523 claims
Astellas Pharma US IncMyrbetriq$1,278$51,13948 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 urology providers in Connecticut.

Other urology in Middlebury

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →